Dianthus Therapeutics, Inc. /DE/ - Common Stock, par value $0.001 per share (DNTH)
CUSIP: 252828108
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 43,212,667
- Total 13F shares
- 35,126,689
- Share change
- +2,962,012
- Total reported value
- $765,706,199
- Put/Call ratio
- 150%
- Price per share
- $21.80
- Number of holders
- 94
- Value change
- +$63,092,353
- Number of buys
- 47
- Number of sells
- 36
Quarterly Holders Quick Answers
What is CUSIP 252828108?
CUSIP 252828108 identifies DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 252828108:
Top shareholders of DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
10%
|
4,403,148
|
$120,558,192 | — | 30 Sep 2024 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
7%
|
3,013,423
|
$82,507,522 | — | 30 Sep 2024 | |
| Avidity Partners Management LP |
13F
|
Company |
6.8%
|
2,917,231
|
$79,873,785 | — | 30 Sep 2024 | |
| Fairmount Funds Management LLC |
13F
3/4/5
|
Company · Director |
6.2%
|
2,700,691
|
$73,944,920 | — | 30 Sep 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
5.4%
|
2,333,000
|
$63,877,540 | — | 30 Sep 2024 | |
| Lei Meng |
3/4/5
|
Director |
—
mixed-class rows
|
4,557,387
mixed-class rows
|
$54,608,811 | — | 22 Jan 2024 | |
| Octagon Capital Advisors LP |
13F
|
Company |
4%
|
1,746,667
|
$47,823,742 | — | 30 Sep 2024 | |
| VR Adviser, LLC |
13F
|
Company |
4%
|
1,744,373
|
$47,760,933 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
3.8%
|
1,644,819
|
$45,035,144 | — | 30 Sep 2024 | |
| Third Rock Ventures IV, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,058,204
|
$36,698,448 | — | 07 Feb 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
3%
|
1,294,969
|
$35,456,250 | — | 30 Sep 2024 | |
| 5AM Venture Management, LLC |
13F
|
Company |
2.9%
|
1,231,619
|
$33,721,728 | — | 30 Sep 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
2.4%
|
1,023,143
|
$28,013,655 | — | 30 Sep 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.2%
|
949,334
|
$25,935,805 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.9%
|
821,131
|
$22,482,567 | — | 30 Sep 2024 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
1.5%
|
666,667
|
$18,253,342 | — | 30 Sep 2024 | |
| Leon O Moulder Jr. |
3/4/5
|
Director |
—
mixed-class rows
|
1,447,745
mixed-class rows
|
$17,240,940 | — | 23 May 2024 | |
| BRAIDWELL LP |
13F
|
Company |
1.1%
|
493,687
|
$13,517,150 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
485,121
|
$13,285,015 | — | 30 Sep 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1%
|
437,700
|
$11,984,226 | — | 30 Sep 2024 | |
| Jason Gardner |
3/4/5
|
Title: President and Chief Executive Officer, Director |
—
class O/S missing
|
944,954
|
$11,339,448 | — | 30 Nov 2022 | |
| Vestal Point Capital, LP |
13F
|
Company |
0.91%
|
395,000
|
$10,815,100 | — | 30 Sep 2024 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.64%
|
275,000
|
$7,529,500 | — | 30 Sep 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.61%
|
264,692
|
$7,247,267 | — | 30 Sep 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.58%
|
250,504
|
$6,858,800 | — | 30 Sep 2024 | |
| Alphabet Inc. |
13F
|
Company |
0.48%
|
208,697
|
$5,714,124 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.47%
|
202,600
|
$5,547,189 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.38%
|
165,929
|
$4,543,136 | — | 30 Sep 2024 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.35%
|
150,000
|
$4,107,000 | — | 30 Sep 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.27%
|
118,738
|
$3,251,046 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.2%
|
88,031
|
$2,410,289 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.19%
|
80,606
|
$2,206,993 | — | 30 Sep 2024 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
0.18%
|
76,979
|
$2,107,685 | — | 30 Sep 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.17%
|
73,015
|
$1,999,150 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.16%
|
67,285
|
$1,842,263 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.15%
|
65,851
|
$1,803,001 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.14%
|
59,301
|
$1,623,661 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.13%
|
55,416
|
$1,517,290 | — | 30 Sep 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.12%
|
53,848
|
$1,474,358 | — | 30 Sep 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.12%
|
53,785
|
$1,472,633 | — | 30 Sep 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.12%
|
50,248
|
$1,375,790 | — | 30 Sep 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.1%
|
42,367
|
$1,160,008 | — | 30 Sep 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.1%
|
41,684
|
$1,141,307 | — | 30 Sep 2024 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0.09%
|
37,100
|
$1,015,798 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.08%
|
34,754
|
$951,565 | — | 30 Sep 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.08%
|
34,617
|
$947,803 | — | 30 Sep 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.07%
|
30,647
|
$839,115 | — | 30 Sep 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.07%
|
30,000
|
$821,400 | — | 30 Sep 2024 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.07%
|
28,931
|
$792,000 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.07%
|
28,428
|
$778,359 | — | 30 Sep 2024 |
Institutional Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock, par value $0.001 per share (DNTH) as of Q4 2024
As of 31 Dec 2024,
Dianthus Therapeutics, Inc. /DE/ - Common Stock, par value $0.001 per share (DNTH) was held by
94 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,126,689 shares.
The largest 10 holders included
FMR LLC, Avidity Partners Management LP, Fairmount Funds Management LLC, Bain Capital Life Sciences Investors, LLC, Octagon Capital Advisors LP, RA CAPITAL MANAGEMENT, L.P., VR Adviser, LLC, BlackRock, Inc., TCG Crossover Management, LLC, and VANGUARD GROUP INC.
This page lists
94
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
90
Q4 2024 holders
94
Holder diff
4
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.